-visit OBiO Tech booth #1644 at the American Society for Gene and Cell Therapy in Maryland. united states of america
Shanghai, April 28, 2024 /PRNewswire/ — OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), the world's leading contract development and manufacturing organization for cell and gene therapies, will be exhibiting at the American Society for Gene and Cell Therapy in Maryland. . united states of america from May 7thth up to 11th. Nine posters will be presented at the American Society for Gene and Cell Therapy.
These presentations include three homegrown and patented achievements, four notable advances in process optimization, and two cutting-edge technologies.
These milestones exemplify OBiO Technology's significant advances in the gene therapy field, including increased vector yield and efficiency, improved treatment processes, and reduced production costs.
OBiO Technology's innovative solutions provide reliable and cost-effective manufacturing methods for gene therapy and advance clinical projects in gene and cell therapy.
OBiO Technology experts share how the company's comprehensive viral vector platform accelerates development schedules, reduces manufacturing risk, and delivers the performance and product quality you need for success at a lower cost i am ready.
“We are delighted to continue our tradition of excellence at the ASGCT conference! OBiO Technology will participate with the utmost enthusiasm and innovative capabilities to present the latest achievements in gene and cell therapy.” said Javier Giaguo, PhD, CEO of OBiO Technology. “Our nine presentations, featuring in-house patented achievements, process optimization breakthroughs, and technology implementations, represent our commitment to continuous innovation and collaborative problem-solving. , also highlights our significant progress in streamlining production processes and reducing costs.''OBiO Technology remains committed to continuous improvement of its forward-looking technology layout and service capabilities, and is committed to the rapid development of the gene and cell therapy industry. Contribute to development. ”
About OBiO technology
OBiO Technology is a leader in the field of gene and cell therapy as a pioneering contract research organization (CRO) and contract development manufacturing organization (CDMO) dedicated to providing comprehensive solutions.
- OBiO Technology's state-of-the-art 830,000 square foot facility ensures superior worldwide supply.
- OBiO Technologies specializes in vectorology research, functional genomics, process and analytical development, ensuring Investigational New Drug (IND) readiness and supporting all stages of clinical and commercial manufacturing.
- With a mission to “Enabling Gene Therapy for Better Lives,” OBiO Technology prioritizes providing top-class services around the world.
- From the lab to the clinic, OBiO Technology continually advances products to positively impact people around the world.
- OBiO Technology's unwavering commitment ensures the delivery of high-quality CDMO services across preclinical, IND, clinical, and commercial stages.
- OBiO Technology's expertise includes plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapies (CAR-T, NK, Tregs), as well as inducible viral vector packaging, ultra-low endotoxin processing, tissue-specific AAV, and more. It also extends to cutting-edge technology. Subspecies.
SOURCE OBiO Technology (Shanghai)Co., Ltd
